Hepatitis C virus infection in the elderly: Epidemiology, natural history and management

Drugs and Aging

Volumn 25, Issue 1, 2008, Pages 9-18

  Cainelli, Francesca ^a,b  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Elderly; Hepatitis C, treatment; Peginterferon alfa 2b ribavirin, therapeutic use; Peginterferon alfa, therapeutic use; Ribavirin, therapeutic use

Indexed keywords

AMANTADINE; BIOCHEMICAL MARKER; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; TARIBAVIRIN;

AGED; ANTIVIRAL THERAPY; COMORBIDITY; CONFUSION; DISEASE COURSE; ELASTOGRAPHY; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; LETHARGY; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL;

EID: 38049000829     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825010-00002     Document Type: Review

References (72)

1. Stroffolini T, Menichelli M, Taliani G, et al. High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure. Ital J Gastroenterol 1995; 27: 235-8
2. Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, et al. Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand J Infect Dis 1996; 28: 17-20
3. Dubois F, Desenclos JC, Mariotte N, et al. Hepatitis C in a French population based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997; 25: 1490-6
4. Osella AR, Misciagna G, Leone A, et al. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol 1997; 27: 30-5
5. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in Southern Italy. Hepatology 1997; 26: 1006-11
6. Maggi G, Armitano S, Brambilla L, et al. Hepatitis C infection in an Italian population not selected for risk factors. Liver 1999; 19: 427-31
7. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44: 874-80
8. Osella AR, Sonzogni L, Cavallini A, et al. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in Southern Italy: a population-based study. J Clin Microbiol 1999; 37: 2371-2
9. Coppola RC, Masia G, Pradat P, et al. Impact of hepatitis C virus infection on healthy subjects on an Italian island. J Viral Hepat 2000; 7: 130-7
10. Maio G, D'Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine aminotransferase levels in the general population: a survey in a southern Italian town. J Hepatol 2000; 33: 116-20
11. Dominguez A, Bruguera M, Vidal J, et al. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001; 65: 688-93
12. Okayama A, Stuver SO, Tabor E, et al. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepat 2002; 9: 43-51
13. Armstrong GL, Simard EP, Wasley A, et al. The prevalence of hepatitis C virus (HCV) infection in the United States 1999-2002 [abstract no. 31]. Hepatology 2004; 40 Suppl. 1: 176A
14. Balogun MA, Ramsay ME, Hesketh LM, et al. The prevalence of hepatitis C in England and Wales. J Infect 2002; 45: 219-26
15. Thierfelder W, Hellenbrand W, Meisel H, et al. Prevalence of markers for hepatitis A, B and C in the German population: results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001; 17: 429-35
16. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82
17. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 Suppl. 1: S35-46
18. Watson JP, Brind AM, Chapman CE, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 1996; 38: 269-76
19. Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6
20. Minola E, Prati D, Suter F, et al. Age of infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002; 99: 4588-91
21. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80
22. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801
23. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-9
24. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754-8
25. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53
26. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-6
27. Kiyosawa K, Tanaka E, Sodeyama T. Hepatitis C virus and hepatocellular carcinoma. Curr Stud Hematol Blood Transfus 1998; 62: 161-80
28. Ben Yehuda A, Globerson A, Krichevsky S, et al. Ageing and the mismatch repair system. Mech Ageing Dev 2000; 121: 173-9
29. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9
30. Wali M, Harrison RP, Gow PJ, et al. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-52
31. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-6
32. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006; 101: 1260-7
33. D'Souza R, Glynn MJ, Ushiro-Lumb I, et al. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005; 3: 910-7
34. Brind AM, Watson JP, James OF, et al. Hepatitis C infection in the elderly. QJM 1996; 89: 291-6
35. Sawabe M, Arai T, Esaki Y, et al. Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases. Liver 1999; 19: 335-42
36. Monica F, Lirussi F, Pregun I, et al. Hepatitis C virus infection in a resident elderly population: a 10-year follow-up study. Dig Liver Dis 2006; 38: 336-40
37. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-63
38. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: American Association for the Study of Liver Diseases. Hepatology 2004; 39: 1147-71
39. Poynard T, Imbert-Bismut F, Munteanu M, et al. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005; 5: 15-21
40. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50
41. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon α-2b and ribavirin. Hepatology 2003; 38: 481-92
42. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65
43. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
44. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36 Suppl. 1: S226-36
45. Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 2003; 11: 208-12
46. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004; 39: 1069-77
47. Koyama R, Arase Y, Ikeda K, et al. Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2006; 49: 121-6
48. Bacosi M, Russo F, D'innocenzo S, et al. Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 2002; 22: 231-9
49. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-14
50. Nudo CG, Wong P, Hilzenrat N, et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006; 20: 589-92
51. Floreani A, Minola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc 2006; 54: 549-50
52. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007; 102: 1383-91
53. Honda T, Katano Y, Urano F, et al. Efficacy of ribavirin plus interferon-alpha in patients aged > or = 60 years with chronic hepatitis C. J Gastroenterol Hepatol 2007; 22: 989-95
54. Flamm SL, Jacobson IM, Brown R, et al. Pegylated interferon alfa 2b + ribavirin are equally efficacious and well tolerated in patients >65 years old in comparison to other age groups: subanalysis of a randomized, controlled study (WIN-R trial) [abstract no. 338]. 57th AASLD; 2006 Oct 27-31; Boston (MA)
55. Gupta SK, Glue P, Jacobs S, et al. Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjects. Br J Clin Pharmacol 2003; 56: 131-4
56. Martin NE, Modi MW, Reddy KR. Characterization of pegylated (40 kDa) interferon α-2A (PEGASYS) in the elderly [abstract no. 755]. Hepatology 2000; 32 (4 Pt 2): 348A
57. Horikawa N, Yamazaki T, Izumi N, et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-α therapy: a prospective study. Gen Hosp Psychiatry 2003; 25: 34-8
58. Roche. Copegus medication guide. Nutley (NJ): Roche, 2007 Jun
59. Schering Plough. Rebetol product information. Kenilworth (NJ): Schering Plough, 2007 Sep
60. Salkowski MS, Wasserman R, Brooks L, et al. Changes in hemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C viral infection. J Viral Hepat 2004; 11: 243-50
61. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon α2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004; 39: 668-73
62. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19: 1312-7
63. Gish RG, Arora S, Nelson D, et al. End-of-treatment (EOT) response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon α-2a [abstract no. 519]. Hepatology 2004; 40 (4 Suppl. 1): 388A
64. Schiff ER. Emerging strategies for pegylated interferon combination therapy. Nat Clin Pract Gastroenterol Hepatol 2007; 4 Suppl. 1: S17-21
65. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9
66. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63
67. Ministry of Health, Labour and Welfare. Abridged life tables for Japan, 2006 [online]. Available from URL: http://www.mhlw.go.jp/ [Accessed 2007 Nov 6]
68. Arias E. United States life tables, 2002. Natl Vital Stat Rep 2004; 53: 1-38
69. Tsui JI, Currie S, Shen H, et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 study. Dig Dis Sci. Epub 2007 Sep 1
70. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50: 16-23
71. Giannitrapani L, Soresi M, La Spada E, et al. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006; 1089: 228-36
72. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007; 27: 186-91